CoChat

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

Open access
Ordóñez, José Luis, Amaral, Ana Teresa, Carcaboso, Angel M., Herrero-Martín, David, García-Macías, María del Carmen, Sevillano, Vicky, Alonso, Diego, Pascual-Pasto, Guillem, San-Segundo, Laura, Vila-Ubach, Monica, Rodrigues, Telmo, Fraile, Susana, Teodosio, Cristina, Mayo-Iscar, Agustín, Aracil, Miguel, Galmarini, Carlos María, Tirado, Oscar M., Mora, Jaume, de Álava, Enrique · 2015 · Oncotarget
Cited by 95

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// José Luis Ordóñez 1,4,* , Ana Teresa Amaral 1,4,* , Angel M. Carcaboso 2 , David Herrero-Martín 3 , María del Carmen García-Macías 4 , Vicky Sevillano 4 , Diego Alonso 4 , Guillem Pascual-Pasto 2 , Laura San-Segundo 4 , Monica Vila-Ubach 2 , Telmo Rodrigues 4 , Susana Fraile 4 , Cristina Teodosio 4 , Agustín Mayo-Iscar 5 , Miguel Aracil 6 , Carlos María Galmarini 6 , Oscar M. Tirado 3 , Jaume Mora 2 and Enrique de Álava 1,4 1 Laboratory of Molecular Pathology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain 2 Developmental Tumor Biology Laboratory, Preclinical Therapeutics and Drug Delivery Research Program, Hospital Sant Joan de Deu Barcelona, Spain 3 Sarcoma Research Group, Laboratori d’Oncología Molecular, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain 4 Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer/Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Salamanca, Spain 5 Statistics and Operations Research Department, University of Valladolid, Spain 6 Cell Biology and Pharmacogenomics Department, Pharmamar, Madrid, Spain * These authors have contributed equally to this work Correspondence to: José Luis Ordóñez García, email: // Enrique de Álava, email: // Keywords : Ewing sarcoma, PARP inhibitor, trabectedin, DNA damage, PDX models Received : March 13, 2015 Accepted : May 13, 2015 Published : May 27, 2015 Abstract Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh disrupts the DDR machinery. Thus, given the impact and apparent specificity of both agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in ES, we decided to explore the activity of combining PARPinh and Trabectedin in in vitro and in vivo experiments. The combination of Olaparib and Trabectedin was found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear accumulation as a result of DNA damage induction, DNA fragmentation and global DDR deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of the drug combination was corroborated in a mouse xenograft model of ES and, more importantly, in two ES patient-derived xenograft (PDX) models in which the tumors showed complete regression. In conclusion, the combination of the two agents leads to a biologically significant deregulation of the DDR machinery that elicits relevant antitumor activity in preclinical models and might represent a promising therapeutic tool that should be further explored for translation to the clinical setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4303

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero-Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual-Pasto, G., San-Segundo, L., Vila-Ubach, M., Rodrigues, T., Fraile, S., Teodosio, C., Mayo-Iscar, A., Aracil, M., Galmarini, C. M., Tirado, O. M., Mora, J., & de Álava, E.
Venue
Oncotarget
Published
2015-05-27
Volume
6
Issue
22
Pages
18875-18890
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1566328614
Cited by
95
References
6
FWCI
4.81
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.